Haiping Dai

Dr. Haiping Dai


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
YHYuan-Hong Huang
Yuan-Hong Huang
CWChao-Ling Wan
Chao-Ling Wan
HDHaiping Dai
Haiping Dai
SXSheng-Li Xue
Sheng-Li Xue

7 February 2022 in Biomarker Research
Verified
Journal Article
Open access
PDF file
HDHaiping Dai
Haiping Dai
WCWei Cui
Wei Cui
QCQing-Ya Cui
Qing-Ya Cui
WZWen-Juan Zhu
Wen-Juan Zhu
HMHui-Min Meng
Hui-Min Meng
XTXiaowen Tang
Xiaowen Tang
Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in almost all T-cell malignancies. Here we present the anti-CD7 CART therapy in a 11-year-old male with TP53 mutated relapsed/refractory ETP-ALL/LBL. The patient suffered second relapse after haploidentical hematopoietic stem cell transplantation, showing resistance to 4 lines salvage therapies including venetoclax. Nanobody derived CD7-CART cells were manufactured by co-transducing CAR-T cells with a CD7 protein expression blocker. 70.5% of blasts (CD7 expression: 92.6%) and extensive extramedullary disease (mediastinal mass, enlarged lymph nodes and spleen) were observed prior to CD7-CART-cell therapy. A total of 5 × 106/kg donor-derived CD7-CART-cells were infused. Hematological and extramedullary remission were both achieved, with persistence of CD7-CART-cells be detected until the last followup at 96th days after the infusion. Reversible adverse effects including grade 3 cytokine release syndrome and macrophage activation syndrome were observed. This case demonstrated that CD7-CART was a potent and safe salvage therapy in relapsed/refractory ETP-ALL/LBL patient with high tumor burden.Trial registration: ClinicalTrials. gov, NCT04785833, Registered on March 8, 2021, prospectively registered.

28 May 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
SGShuai‐Shuai Ge
Shuai‐Shuai Ge
QQQiao‐Cheng Qiu
Qiao‐Cheng Qiu
HDHaiping Dai
Haiping Dai
XSXiang‐Dong Shen
Xiang‐Dong Shen
TWTian‐Mei Wu
Tian‐Mei Wu
SLSongbai Liu
Songbai Liu

4 September 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
WCWei Cui
Wei Cui
XZXin‐Yue Zhang
Xin‐Yue Zhang
ZLZheng Li
Zheng Li
HDHaiping Dai
Haiping Dai
JYJia Yin
Jia Yin
XTXiao‐Wen Tang
Xiao‐Wen Tang

18 January 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
YLYan-Yan Li
Yan-Yan Li
SGShuai-Shuai Ge
Shuai-Shuai Ge
YHYuan-Hong Huang
Yuan-Hong Huang
MXMing-Zhu Xu
Ming-Zhu Xu
CWChao-Ling Wan
Chao-Ling Wan
HDHaiping Dai
Haiping Dai

18 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPCheryl A. C. Peretz
Cheryl A. C. Peretz
VKVanessa E. Kennedy
Vanessa E. Kennedy
AWAnushka Walia
Anushka Walia
CDCyrille L. Delley
Cyrille L. Delley
AKAndrew Koh
Andrew Koh
CSCatherine C. Smith
Catherine C. Smith
Despite recent work linking mixed phenotype acute leukemia (MPAL) to certain genetic lesions, specific driver mutations remain undefined for a significant proportion of patients and no genetic subtype is predictive of clinical outcomes. Moreover, therapeutic strategy for MPAL remains unclear, and prognosis is overall poor. We performed multiomic single cell profiling of 14 newly diagnosed adult MPAL patients to characterize the inter- and intra-tumoral transcriptional, immunophenotypic, and genetic landscapes of MPAL. We show that neither genetic profile nor transcriptome reliably correlate with specific MPAL immunophenotypes. Despite this, we find that MPAL blasts express a shared stem cell-like transcriptional profile indicative of high differentiation potential. Patients with the highest differentiation potential demonstrate inferior survival in our dataset. A gene set score, MPAL95, derived from genes highly enriched in the most stem-like MPAL cells, is applicable to bulk RNA sequencing data and is predictive of survival in an independent patient cohort, suggesting a potential strategy for clinical risk stratification.